



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Loqtorzi

Page: 1 of 4

Effective Date: 8/7/2025

Last Review Date: 7/2025

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Arizona
	<input type="checkbox"/> Kentucky PRMD		

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Loqtorzi under the patient's prescription drug benefit.

Description:

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications¹

- Loqtorzi is indicated, in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC).
- Loqtorzi is indicated, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

Compendial Uses^{2,3}

- Nasopharyngeal Carcinoma (NPC)
- Anal Carcinoma
- Small Bowel Adenocarcinoma
- Colorectal Cancer
- Non-small Cell Lung Cancer (NSCLC)

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

Loqtorzi

Policy/Guideline:

Documentation

Submission of the following information is necessary to initiate the prior authorization review:



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Loqtorzi

Page: 2 of 4

Effective Date: 8/7/2025

Last Review Date: 7/2025

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Arizona
	<input type="checkbox"/> Kentucky PRMD		

- Documentation of laboratory report confirming microsatellite instability-high (MSI-H), mismatch repair deficient (dMMR) or polymerase epsilon/delta (POLE/POLD1) tumor status, where applicable.
- Documentation of the absence of epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations, where applicable.

Exclusions

Coverage will not be provided for members who have experienced disease progression while on PD-1 or PD-L1 inhibitor therapy.

Coverage Criteria

Nasopharyngeal Carcinoma (NPC)^{1,2}

Authorization of 6 months may be granted when either of the following criteria are met:

- The requested medication will be used in combination with cisplatin and gemcitabine for the treatment of unresectable, metastatic or recurrent locally advanced NPC.
- The requested medication will be used as a single agent for treatment of recurrent, unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

Anal Carcinoma²

Authorization of 6 months may be granted as a single agent for subsequent treatment of metastatic anal carcinoma if the member has not received prior immunotherapy.

Small Bowel Adenocarcinoma²

Authorization of 6 months may be granted as a single agent for treatment of locally unresectable, medically inoperable, advanced or metastatic small bowel adenocarcinoma for microsatellite instability-high (MSI-H), or deficient mismatch repair (dMMR), or polymerase epsilon/delta (POLE/POLD1) mutation with ultra-hypermutated phenotype tumors.

Colorectal Cancer²

Authorization of 6 months may be granted as a single agent for the treatment of unresectable, medically inoperable, advanced, or metastatic colorectal cancer, including appendiceal adenocarcinoma, for microsatellite instability-high (MSI-H), or deficient mismatch repair (dMMR), or polymerase epsilon/delta (POLE/POLD1) mutation with ultra-hypermutated phenotype tumors.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Loqtorzi

Page: 3 of 4

Effective Date: 8/7/2025

Last Review Date: 7/2025

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Arizona
	<input type="checkbox"/> Kentucky PRMD		

Non-small Cell Lung Cancer (NSCLC)³

Authorization of 6 months may be granted:

- For treatment of advanced NSCLC when there are no EGFR or ALK mutations (unless testing is not feasible due to insufficient tissue) and the requested medication will be used as a first-line treatment in combination with platinum-doublet chemotherapy and then continued as single agent maintenance therapy.
- As neoadjuvant treatment if there are no EGFR or ALK mutations (unless testing is not feasible due to insufficient tissue) when used in combination with platinum-doublet chemotherapy and then continued as single agent adjuvant therapy after surgery.

Continuation of Therapy

Nasopharyngeal Carcinoma

Authorization of 6 months (for up to 24 months total when being used as first line therapy) may be granted for continued treatment in members requesting reauthorization for nasopharyngeal carcinoma when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

Neoadjuvant NSCLC

Authorization of 6 months may be granted (up to 13 cycles total) for continued treatment in members requesting reauthorization for neoadjuvant treatment of NSCLC who have not experienced disease progression or an unacceptable toxicity.

NSCLC

Authorization of 6 months (for up to 24 months total) may be granted for continued treatment in members requesting reauthorization for NSCLC when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

All Other Indications

Authorization of 6 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

Approval Duration and Quantity Restrictions:

Approval: 6 months

References:

1. Loqtorzi [package insert]. Redwood City, CA: Coherus BioSciences, Inc; October 2024.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Loqtorzi

Page: 4 of 4

Effective Date: 8/7/2025

Last Review Date: 7/2025

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Arizona
	<input type="checkbox"/> Kentucky PRMD		

2. The NCCN Drugs & Biologics Compendium 2025 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed March 4, 2025.
3. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at <https://www.micromedexsolutions.com> Accessed March 6, 2025.